If approved, the fully liquid presentation will offer healthcare providers an option that does not require reconstitution of Menveo (MenACWY vaccine) before use
Marketing authorisation in EU expected by November 2024
Over 6 million doses of GSK’s MenACWY vaccine have been distributed to European countries since 2017 to help protect against invasive meningococcal disease1
GSK plc (LSE/NYSE: GSK) today announced that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended for use a single-vial, fully liquid presentation of Menveo (Meningococcal Group A, C, W-135 and Y conjugate vaccine, MenACWY vaccine) to help protect against invasive meningococcal disease (IMD) caused by bacterial groups A, C, W, and Y.

If approved, this single-vial presentation will be licenced for active immunisation of children from 2 years of age, adolescents and adults, offering healthcare providers an option that does not require reconstitution before its use.

Philip Dormitzer, GSK Head of Global Vaccines Research & Development, said: “As a global leader in meningococcal vaccines, we are committed to finding innovative solutions that simplify immunisation against bacterial meningitis, support vaccine uptake and help protect as many people as possible from this devastating disease. We will continue our efforts to help prevent this disease in at-risk populations in the European Union.”

GSK’s submission to the EMA is based on two positive Phase IIb trials (2017-003692-61; 2017-003456-23).2,3 The primary and secondary outcomes of these trials, supported by post-hoc pooled analyses, show that the fully liquid formulation of this vaccine has comparable immunogenicity, tolerability and a comparable safety profile to the existing lyophilized/liquid formulation. Today’s positive opinion marks one of the final steps prior to the potential extension of the marketing authorisation by the European Commission (EC). The EC’s final decision is expected by November 2024.

IMD is an unpredictable but serious illness that can cause life-threatening complications.4 Despite treatment, among those who contract IMD one in six will die, sometimes in as little as 24 hours.4 One in five survivors may suffer long-term consequences such as brain damage, amputations, hearing loss and nervous system problems.4 Although anyone can get IMD, babies, young children and those who are in their late teens and early adulthood are amongst the groups at higher risk.4

The original presentation of Menveo that requires reconstitution and which was approved by the EMA in 2010 is unaffected by this recommendation.5

About Menveo
GSK’s MenACWY vaccine has received regulatory approval in over 60 countries, with more than 82 million doses distributed worldwide since 2010.6,7 Over 6 million doses have been distributed to European countries since 2017.1 It offers evidence of immunogenicity with a well-characterised safety profile.8,9 In the European Union (EU), this vaccine has received regulatory approval for active immunisation to prevent IMD caused by Neisseria meningitidis serogroups A, C, Y, and W in children from 2 years of age, adolescents and adults.10 EMA Prescribing Information for Menveo can be accessed at: https://www.ema.europa.eu/en/medicines/human/EPAR/menveo

About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

Cautionary statement regarding forward-looking statements
see read more on
https://www.gsk.com/en-gb/media/press-releases/gsk-s-menveo-meningococcal-vaccine-in-new-single-vial-fully-liquid-presentation-receives-positive-european-chmp-opinion/